Cancer Cell：王吉光/江涛团队提出基于蛋白的IDH突变型星形细胞瘤分型，发现预后不良的免疫热亚型，并开发出AI诊断工具

Core Insights - The article discusses the research on IDH-mutant astrocytoma, highlighting its aggressive nature and poor prognosis despite advancements in molecular diagnostics [2][9] - A new classification system based on protein profiling has been developed, identifying four molecular subtypes of IDH-mutant astrocytoma, with a focus on the immune-hot subtype (IME) that is associated with worse outcomes [3][10] Molecular Subtypes - The study defines four molecular subtypes of IDH-mutant astrocytoma: AFM, PPR, IME, and NEU, with IME being characterized by significant immune infiltration and poor prognosis [3][7] - The IME subtype accounts for approximately 13% of IDH-mutant astrocytomas and shows a tendency to evolve during tumor recurrence [7][10] Prognostic Factors - The research indicates that the presence of CDKN2A/B gene homozygous deletions is a diagnostic criterion for WHO grade 4 IDH-mutant astrocytoma, while MYC gene amplification suggests aggressive tumor progression [5][10] - The study emphasizes the importance of protein-based classification in predicting survival outcomes and treatment responses, which is more effective than transcriptomic approaches [6][10] AI Diagnostic Tool - An AI-driven diagnostic tool named GUIDE has been developed, which integrates multimodal data including histopathological images, transcriptomics, proteomics, and DNA methylation data for accurate patient stratification [8][10] - This tool supports both single-modal and multi-modal inputs, enhancing the precision of patient classification [8][10]